Analysts think INDP stock price could increase by 332%
Jun 14, 2024, 6:29 AM
-8.47%
What does INDP do
Indaptus Therapeutics, Inc., a pre-clinical biotechnology company based in New York City, focuses on developing cancer immunotherapy, targeting unresectable or metastatic solid tumors and lymphomas. Their lead product, Decoy20, targets tumor and viral antigens using a platform that activates both innate and adaptive immunity, delivered intravenously to stimulate immune response in key organs and tumors.
4 analysts think INDP stock price will increase by 332.20%. The current median analyst target is $10.20 compared to a current stock price of $2.36. The lowest analysts target is $8.08 and the highest analyst target is $12.60.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
